Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameAnti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD22Anti-CD19

TargetsB-lymphocyte antigen CD19CD22

Therapy Area/IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesThe Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine

Active IndicationsN/A

Inactive IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A